**Star News, Garden Biology (300401) replied to investors' concerns on the investor relations platform on December 02.
Investors:Would you consider cooperating with Huawei to help you develop new products and improve production management and efficiency through big data?Thank you.
Garden Biology Board Secretary:Dear Investors: Hello, thank you for your comments and suggestions. Thank you.
Investors:What is the production status of the ninth batch of bid-winning drugs?
Garden Biology Board Secretary:Dear Investors: Hello, thank you for your attention. Omeprazole sodium bicarbonate capsules, which were selected by Huayuan Pharmaceutical in the ninth batch of national centralized drug procurement, are currently being produced and verified as planned, and are expected to enter the market in the first half of 2024 according to the implementation arrangements of the selected provinces and cities. Thank you.
Investors:What is the progress of shrimp feed additives standards?
Garden Biology Board Secretary:Dear Investors: Hello, thank you for your attention. The Company will fulfill its information disclosure obligations in a timely manner according to the progress. Thank you.
Investors:Are discussions continuing on the joint venture with DSM?
Garden Biology Board Secretary:Dear Investors: Hello, thank you for your attention. Thank you.
Investors:The current stock price is relatively low, which belongs to the market low and the company's historical low. Is your company's buyback still in progress?Or wait for the stock price to double before repurchasing it?Thank you.
Garden Biology Board Secretary:Dear Investors: Hello, thank you for your attention. The company's share repurchase plan is ongoing, please pay attention to the company's share repurchase progress announcement in a timely manner. Thank you.
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you, investment is risky, please make a cautious decision.